The average P/S ratio for NEO's competitors is 0.74, providing a benchmark for relative valuation. Neogenomics Inc Corp (NEO) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 7.55%, this premium appears unsustainable.